Translation of randomised controlled trial findings into clinical practice: Comparison of olanzapine and valproate in the EMBLEM study

Pharmacopsychiatry

Volumn 42, Issue 4, 2009, Pages 145-152

  Novick, D ^a   Gonzalez Pinto, A ^b   Haro, J M ^c   Bertsch, J ^c   Reed, C ^a   Perrin, E ^a   Tohen, M ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Hospital Santiago   (Spain)

^c PARC SANITARI SANT JOAN DE DÉU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; HYPNOTIC AGENT; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; VALPROIC ACID; TRANQUILIZER;

ADULT; AKATHISIA; AMNESIA; ARTICLE; BIPOLAR DISORDER; BIPOLAR MANIA; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DYSTONIA; FEMALE; GASTROINTESTINAL SYMPTOM; HAMILTON SCALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MANIA; MENSTRUATION DISORDER; MENTAL CONCENTRATION; MONOTHERAPY; NOCTURIA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PARKINSONISM; POLYURIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; REMISSION; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; WEIGHT; YOUNG MANIA RATING SCALE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; GASTROINTESTINAL DISEASE; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; WEIGHT GAIN;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VALPROIC ACID; WEIGHT GAIN;

EID: 70249084580     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0028-1128115     Document Type: Article

References (42)

1. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002 ; 159 (Suppl) : 1-50
2. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000 ; 342 : 1878-1886
3. Bowden CL, Brugger AM, Swann AC et al. Efficacy of divalproex versus lithium and placebo in the treatment of mania. JAMA 1994 ; 271 : 918-924
4. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000 ; 342 : 1887-1892
5. Ghaemi SN, Hsu DJ, Thase ME et al. Pharmacological treatment patterns at study entry for the first 500 STEP-BD participants. Psychiatric Services 2006 ; 57 : 660-665
6. Goetz I, Tohen M, Reed C et al., EMBLEM Advisory Board. Functional impairment in patients with mania: baseline results of the EMBLEM study. Bipolar Disord 2007 ; 9 : 4 5-52
7. Gonzalez-Pinto A, Ballesteros J, Aldama A et al. Principal components of mania. J Affect Disord 2003 ; 76 : 95-102
8. Goodwin GM, Consensus Group of the British Association for Psychopharmacology . Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology . J Psychopharmacol 2003 ; 17 : 149-173
9. Grunze H, Kasper S, Goodwin G et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of mania. World J Biol Psychiatry 2003 ; 4 : 5-13
10. Haro JM, Kontodimas S, Negrin MA et al. Methodological aspects in the assessment of treatment effects in observational health outcome studies. Appl Health Econ Health Policy 2006 ; 5 : 1 1-25
11. Haro JM, Suarez D, Novick D et al., SOHO Study Group. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmcol 2007 ; 17 : 235-244
12. Haro JM, Van Os J, Vieta E et al., EMBLEM Advisory Board. Evidence for three distinct classes of ' typical ', ' psychotic' and ' dual' mania: results from the EMBLEM study. Acta Psychiatr Scand 2006 ; 113 : 112-120
13. Ioannidis JP, Haidich AB, Pappa M et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA 2001 ; 286 : 821-830
14. Judd LL, Akisal HS, Schettler PJ et al. Psychosocial disability in the course of bipolar I and II disorders. Arch Gen Psychiatry 2005 ; 62 : 1322-1330
15. Kessler RC, MacGonagle KA, Zhao S et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994 ; 51 : 8-19
16. Leverich GS, Nolen WA, Rush AJ et al. The Stanley Foundation Bipolar Treatment Outcome Network. I. Longitudinal methodology. J Affect Disord 2001 ; 67 : 33-44
17. Licht RW, Vestergaard P, Kessing LV et al., Danish Psychiatric Association and the Child and Adolescent Psychiatric Association in Denmark. Psychopharmacological treatment with lithium and antiepileptic drugs: suggested guidelines from the Danish Psychiatric Association and the Child and Adolescent Psychiatric Association in Denmark. Acta Psychiatr Scand Suppl 2003 ; 419 : 1-22
18. Lieberman JA, Stroup TS, MacEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 ; 353 : 1209-1223
19. Lu M-L. Olanzapine reduces mania more effectively than divalproex, but has more adverse effects. Evid Based Ment Health 2003 ; 6 : 28
20. Marneros A. Affective disorders: basic principles regarding clinical course, long-term therapeutic and prophylactic strategies. Pharmacopsychiatry 2004 ; 37 (Suppl. 2) : S148-S151
21. Merikangas KR, Akiskal HS, Angst J et al. Lifetime and 12-month prevalence of bipolar disorder spectrum disorder in the national comorbidity survey replication. Arch Gen Psychiatry 2007 ; 64 : 543-552
22. National Institute of Health and Clinical Excellence (NICE). Bipolar Disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. NICE Clinical Guideline 2006 ; 38, Available at: www.nice.org.uk/CG038
23. Perlis RH, Ostacher MJ, Patel JK et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2006 ; 163 : 217-224
24. Pini S, Q ueiroz V De, P agnin D et a l. P revalence and burden of bipolar disorders in European countries. Eur Neuropsychopharmacol 2005 ; 15 : 425-434
25. Pope HG, MacElroy SL, Keck PE et al. Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry 1991 ; 48 : 62-68
26. Rush AJ. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association ; 2000
27. Sachs GS, Printz DJ, Kahn DA et al. The Expert Consensus Guideline Series: Medication treatment of bipolar disorder 2000. Postgrad Med April 2000, Spec No: 1-104
28. Schuepbach D, Novick D, Haro JM et al. Determinants of voluntary vs. involuntary admission in bipolar disorders and the impact of adherence . Pharmacopsychiatry 2008 ; 41 : 29-36
29. Stensland MD, Ranjan R, Faries D et al The effectiveness of olanzapine vs. divalproex in clinical practice: a 1-year study of the treatment of mixed, manic and hypomanic. 159th Annual Meeting of the American Psychiatric Association. Toronto, Canada: American Psychiatric Association ; 2006, (Abstract)
30. Suppes T, Brown E, Schuh LM et al. Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47- week data. J Affect Disord 2005 ; 89 : 69-77
31. Swann AC, Bowden CL, Calabrese JR et al. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am J Psychiatry 1999 ; 156 : 1264-1266
32. Tohen M, Angst J. Epidemiology of Bipolar Disorder. In Tohen M, Tsang MT, eds. Textbook in Psychiatric Epidemiology, 2nd ed. New York: John Wiley & Sons ; 2002 ; 427-444
33. Tohen M, Baker RW, Altshuler LL et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002 ; 159 : 1011-1017 (Pubitemid 34586948)
34. Tohen M, Jacobs TG, Grundy SL et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2000 ; 57 : 841-849
35. Tohen M, Sanger TM, MacElroy SL et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999 ; 156 : 702-709 (Pubitemid 29220067)
36. Tohen M, Vieta E, Calabrese J et al. Efficacy of olanzapine and olanzapine- fl uoxetine combination in the treatment of bipolar II depression. Arch Gen Psychiatry 2003 ; 60 : 1079-1088
37. Tohen M, Waternaux CM, Tsuang MT. Outcome in Mania. A four year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psych 1990 ; 47 : 1106-1111
38. Vieta E. Divalproex versus olanzapine in mania. J Clin Psychiatry 2003 ; 64 : 1266
39. Vieta E, Calabrese JR, Hennen J et al. Comparison of rapid-cycling and non-rapid-cycling bipolar I manic patients during treatment with olanzapine: analysis of pooled data. J Clin Psychiatry 2004 ; 65 : 1420-1428
40. Wells KB. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Am J Psychiatry 1999 ; 156 : 5-10
41. Young RC, Biggs JT, Ziegler VE et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978 ; 133 : 429-435
42. Zajecka JM, Weisler R, Sachs G et al. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002 ; 63 : 1148-1155